Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted For Presentation At AASLD - The Liver Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma Corporation (NASDAQ:ABUS) will present clinical data on its RNAi therapeutic, imdusiran, at the AASLD Liver Meeting 2024. The data includes results from the IM-PROVE I and II Phase 2a trials.
October 15, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma will present promising clinical data on imdusiran at a major liver disease conference, potentially boosting investor confidence.
The presentation of clinical data at a major conference like AASLD can increase visibility and credibility for Arbutus Biopharma's imdusiran. Positive data from the IM-PROVE I and II trials could lead to increased investor interest and a potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100